-
公开(公告)号：WO2020159368A1
公开(公告)日：2020-08-06
申请号：PCT/NL2020/050051
申请日：2020-01-30
Applicant: LAVA THERAPEUTICS B.V. , STICHTING VUmc
Inventor： VAN DER VLIET, Johannes Jelle , DE WEERDT, Iris , DE GRUIJL, Tanja Denise , PARREN, Paul , KATER, Aron Philip , SCHEFFER, George Lodewijk
Abstract: The present invention relates to novel antibodies capable of binding human CD40 and to novel multispecific antibodies capable of binding human CD40 and capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.
-
公开(公告)号：US20220135694A1
公开(公告)日：2022-05-05
申请号：US17427291
申请日：2020-01-30
Applicant: LAVA THERAPEUTICS B.V.
Inventor： Johannes Jelle VAN DER VLIET , Iris DE WEERDT , Tanja Denise DE GRUIJL , Paul PARREN , Aron Philip KATER , George Lodewijk SCHEFFER
Abstract: The present invention relates to novel antibodies capable of binding human CD40 and to novel multispecific antibodies capable of binding human CD40 and capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.
-
公开(公告)号：US20190263908A1
公开(公告)日：2019-08-29
申请号：US16414424
申请日：2019-05-16
Applicant: LAVA THERAPEUTICS B.V.
IPC: C07K16/28
Abstract: The invention is in the field of medicine and relates to immunology, and relates in particular to human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules. Human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human Vγ9Vδ2 T cells, wherein human Vγ9Vδ2 T cells may be modulated
-
公开(公告)号：US20180142020A1
公开(公告)日：2018-05-24
申请号：US15546406
申请日：2016-01-27
Applicant: LAVA THERAPEUTICS B.V.
Inventor： Johannes Jelle VAN DER VLIET , Tanja Denise DE GRUIJL , Hendrik Marinus Willem VERHEUL , Renée Cornelia Gerarda DE BRUIN , Roeland LAMERIS
CPC classification number: C07K16/2809 , C07K16/2833 , C07K16/30 , C07K2317/565 , C07K2317/569 , C07K2317/75
Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.
-
公开(公告)号：US20210371525A1
公开(公告)日：2021-12-02
申请号：US17277984
申请日：2019-09-19
Applicant: LAVA THERAPEUTICS B.V.
Inventor： Iris DE WEERDT , Arnon Philip KATER , Paul Willem Henri Ida PARREN , Tanja Denise DE GRUIJL , Johannes Jelle VAN DER VLIET , Roeland LAMERIS
Abstract: The present invention relates to novel methods for the treatment of hematological malignancies. In particular, the invention relates to the treatment of hematological malignancies using antibodies comprising a first binding moiety that is able to bind human CD1d and a second binding moiety that is able to bind the human Vγ9Vδ2-TCR.
-
Patent Agency Ranking
公开(公告)号：US20220111043A1
公开(公告)日：2022-04-14
申请号：US17277906
申请日：2019-09-19
Applicant: LAVA THERAPEUTICS B.V.
Inventor： Johannes Jelle VAN DER VLIET , Roeland LAMERIS , Tanja Denise DE GRUIJL , Paul Willem Henri Ida PARREN
IPC: A61K39/395 , A61P35/00
Abstract: The present invention relates to the field of immunology, more in particular to the field of binding moieties and/or immunoglobulins which bind to human CD1d, including antibodies and fragments thereof that modify CD1d-mediated biological functions such as enhanced activation and reduced activation of CD1d-restricted T cells, including the natural killer T-cells and gamma-delta T-cells, and modulation of the function of cells expressing CD1d. The invention also relates to bi-, tri- or multi-specific immunoglobulins that bind to CD1d and a gamma-delta TCR and/or a tumor target. The invention further relates to pharmaceutical preparations and use of such mono-, bi-, and tri- or multi-specific binding moieties and/or immunoglobulins in the treatment of diseases or disorders.
-
公开(公告)号：WO2020060406A1
公开(公告)日：2020-03-26
申请号：PCT/NL2019/050625
申请日：2019-09-19
Applicant: LAVA THERAPEUTICS B.V.
Inventor： DE WEERDT, Iris , KATER, Arnon Philip , PARREN, Paul Willem Henri Ida , DE GRUIJL, Tanja Denise , VAN DER VLIET, Johannes Jelle , LAMERIS, Roeland
IPC: C07K16/28 , A61K39/395 , A61P35/04
Abstract: The present invention relatestonovel methodsfor the treatment of hematological malignancies. In particular, the invention relatesto the treatment of hematological malignancies using antibodiescomprising a first binding moiety that is able to bind human CD1d and a second binding moiety that is able to bind the human Vγ9Vδ2-TCR.
-
8.发明申请
公开(公告)号：WO2021052995A1
公开(公告)日：2021-03-25
申请号：PCT/EP2020/075831
申请日：2020-09-16
Applicant: LAVA THERAPEUTICS B.V.
Inventor： ROOVERS, Robertus Cornelis , HORBACH, Gerard Joseph Maria Jean , RIEDL, Thilo Alexander , VAN DER VLIET, Johannes Jelle , PARREN, Paul Willem Henri Ida
Abstract: The invention relates to methods for the treatment of cancer. In particular, the invention relates to methods for the treatment of cancer, comprising administration of a high dose of an antibody capable of binding a human Vγ9Vẟ2 T cell receptor.
-
公开(公告)号：WO2020060405A1
公开(公告)日：2020-03-26
申请号：PCT/NL2019/050624
申请日：2019-09-19
Applicant: LAVA THERAPEUTICS B.V.
Inventor： VAN DER VLIET, Johannes Jelle , LAMERIS, Roeland , DE GRUIJL, Tanja Denise , PARREN, Paul Willem Henri Ida
IPC: C07K16/28 , A61K39/395 , A61P35/04
Abstract: The present invention relates to the field of immunology, more in particular to the field of binding moieties and/or immunoglobulins which bind to human CD1d, including antibodies and fragments thereof that modify CD1d-mediated biological functions such as enhanced activation and reduced activation of CD1d-restricted T cells, including the natural killer T- cells and gamma-delta T-cells, and modulation of the function of cells expressing CD1d. The invention also relates to bi-, tri-or multi-specific immunoglobulins that bind to CD1d and a gamma-delta TCR and/or a tumor target. The invention further relates to pharmaceutical preparations and use of such mono-, bi-,and tri-or multi-specific binding moieties and/or immunoglobulins in the treatment of diseases or disorders.
-
公开(公告)号：EP3853256A1
公开(公告)日：2021-07-28
申请号：EP19831921.2
申请日：2019-09-19
Applicant: Lava Therapeutics B.V.
Inventor： VAN DER VLIET, Johannes Jelle , LAMERIS, Roeland , DE GRUIJL, Tanja Denise , PARREN, Paul Willem Henri Ida
IPC: C07K16/28 , A61K39/395 , A61P35/04
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.023 seconds)
